CDC: Nirsevimab 90% Effective Against RSV Hospitalization in Infants

(MedPage Today) -- Immunizing infants in their first respiratory syncytial virus (RSV) season with nirsevimab (Beyfortus) proved highly protective against severe disease, a case-control study showed. From October 2023 through February 2024, the...
Source: MedPage Today Public Health - Category: American Health Source Type: news